透视引导泡沫硬化剂治疗腿部静脉曲张:长期随访的回顾性队列分析
本回顾性队列研究纳入2011年8月1日至2016年5月31日在该中心连续接受透视引导泡沫硬化剂治疗腿部静脉曲张的患者,2022年5月通过电话/微信交互访谈进行末次随访。最终分析94例患者(58.3±7.8岁;43例男性;119条腿),中位CEAP临床分级3.0(IQR 3.0,4.0),C5和C6占5.0%(6/119)。术中平均泡沫硬化剂总用量35±12 mL(范围10-75 mL)。无患者发生卒中、深静脉血栓形成或肺栓塞。末次随访时中位CEAP临床分级降低3.0,除class 5外所有119条腿CEAP临床分级至少降低一个等级。中位静脉临床严重程度评分末次随访2.0(IQR 1.0,5.0) vs 基线7.0(IQR 5.0,8.0),P < .001。总体复发率30.9%(29/94),大隐静脉26.6%(25/94) vs 小隐静脉4.3%(4/94),P < .001。5例患者接受后续手术治疗,其余患者选择保守治疗。基线2条C5腿中,1条腿治疗后3个月溃疡复发,经保守治疗后愈合。基线4条C6腿中,所有患者溃疡在1个月内愈合。色素沉着发生率11.8%(14/119)。结论:接受透视引导泡沫硬化剂治疗的患者长期结局令人满意,短期安全性顾虑极少。
要点
- 末次随访中位CEAP临床分级降低3.0,除class 5外所有腿CEAP临床分级至少降低一个等级。
- 中位静脉临床严重程度评分末次随访2.0 vs 基线7.0,P < .001。
- 总体复发率30.9%(29/94),大隐静脉26.6%(25/94) vs 小隐静脉4.3%(4/94),P < .001。
核心结论
- 接受透视引导泡沫硬化剂治疗的患者长期结局令人满意,短期安全性顾虑极少。
研究设计与样本
- 回顾性队列研究,纳入2011年8月1日至2016年5月31日在该中心连续接受透视引导泡沫硬化剂治疗腿部静脉曲张的患者,末次随访为2022年5月通过电话/微信交互访谈进行,最终分析94例患者(58.3±7.8岁;43例男性;119条腿)。
主要发现
- 中位CEAP临床分级为3.0(IQR 3.0,4.0),C5和C6占5.0%(6/119)。
- 术中平均泡沫硬化剂总用量35±12 mL(范围10-75 mL)。
- 无患者发生卒中、深静脉血栓形成或肺栓塞。
- 末次随访中位CEAP临床分级降低3.0,除class 5外所有119条腿CEAP临床分级至少降低一个等级。
- 中位静脉临床严重程度评分末次随访2.0(IQR 1.0,5.0) vs 基线7.0(IQR 5.0,8.0),P < .001。
关键数值与推荐
- 复发定义为存在静脉曲张 regardless of symptoms。
- 总体复发率30.9%(29/94),大隐静脉26.6%(25/94) vs 小隐静脉4.3%(4/94),P < .001。
- 色素沉着发生率11.8%(14/119)。
- 基线2条C5腿中,1条腿治疗后3个月溃疡复发,经保守治疗后愈合;基线4条C6腿中,所有患者溃疡在1个月内愈合。
- 5例患者接受后续手术治疗,其余患者选择保守治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the long-term effectiveness of fluoroscopy-guided foam sclerotherapy for varicose veins in the legs. METHODS: This retrospective cohort study included consecutive patients who underwent fluoroscopy-guided foam sclerotherapy for varicose veins in the legs at the authors' center during a period from August 1, 2011, to May 31, 2016. The last follow-up was conducted by a telephone/WeChat interactive interview in May 2022. Recurrence was defined as the presence of varicose veins regardless of symptoms. RESULTS: The final analysis included 94 patients (58.3 ± 7.8 years of age; 43 men; 119 legs). The median Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical class was 3.0 (interquartile range [IQR]: 3.0, 4.0). C5 and C6 accounted for 5.0% (6/119) of the legs. The average total amount of the foam sclerosant used during the procedure was 35 ± 12 mL (range: 10-75 mL). No patients developed stroke, deep vein thrombosis, or pulmonary embolism after the treatment. At the last follow-up, the median CEAP clinical class reduction was 3.0. All 119 legs except for class 5 achieved the CEAP clinical class reduction by at least one grade. The median venous clinical severity score was 2.0 (IQR: 1.0, 5.0) at the last follow-up vs 7.0 (IQR: 5.0, 8.0) at the baseline (P < .001). The recurrence rate was 30.9% (29/94) in the overall analysis, 26.6% (25/94) for the great saphenous vein and 4.3% (4/94) for the small saphenous vein (P < .001). Five patients received subsequent surgical treatment, and the remaining patients opted to receive conservative treatments. Among the two C5 legs at the baseline, ulcer recurred in one leg at 3 months after the treatment and healed after conservative treatments. In the four C6 legs at the baseline, ulcer healed within a month in all patients. The rate of hyperpigmentation was 11.8% (14/119). CONCLUSIONS: Long-term outcomes in patients undergoing fluoroscopy-guided foam sclerotherapy are satisfying, with minimal short-term safety concerns.
引用
- Zhu Y, Wu D, Song K, et al. Fluoroscopy-guided foam sclerotherapy for varicose veins in the legs: A retrospective cohort analysis with long-term follow-up. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 36906106. doi:10.1016/j.jvsv.2023.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。